Exploring Mechanism of Modified Fuzi Lizhongtang in Intervening Inflammatory Response of Intestinal Mucosa in Rats with Ulcerative Colitis Based on mTOR/p-S6K1

Yan-wei HAO; Yi ZHANG; Xue-lei ZHOU; Jun-rong YU; Jin-hao ZENG; Yu GUO

doi:10.13422/j.cnki.syfjx.20201340

您当前的位置：

首页 >

文章列表页 >

Exploring Mechanism of Modified Fuzi Lizhongtang in Intervening Inflammatory Response of Intestinal Mucosa in Rats with Ulcerative Colitis Based on mTOR/p-S6K1

Classic Prescriptions | 更新时间：2020-08-11

- Exploring Mechanism of Modified Fuzi Lizhongtang in Intervening Inflammatory Response of Intestinal Mucosa in Rats with Ulcerative Colitis Based on mTOR/p-S6K1
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 13, Pages: 59-65(2020)
- 作者机构：
  
  成都中医药大学附属医院，成都 610075
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201340
  CLC： R2-0;R285.5;R318.14
- Published Online：20 April 2020，
  
  Published：05 July 2020
- 稿件说明：
移动端阅览
郝彦伟,张怡,周雪雷等.基于mTOR/p-S6K1探讨加味附子理中汤干预UC大鼠肠黏膜炎症反应的效应机制[J].中国实验方剂学杂志,2020,26(13):59-65.

HAO Yan-wei,ZHANG Yi,ZHOU Xue-lei,et al.Exploring Mechanism of Modified Fuzi Lizhongtang in Intervening Inflammatory Response of Intestinal Mucosa in Rats with Ulcerative Colitis Based on mTOR/p-S6K1[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(13):59-65.
郝彦伟,张怡,周雪雷等.基于mTOR/p-S6K1探讨加味附子理中汤干预UC大鼠肠黏膜炎症反应的效应机制[J].中国实验方剂学杂志,2020,26(13):59-65. DOI： 10.13422/j.cnki.syfjx.20201340.

HAO Yan-wei,ZHANG Yi,ZHOU Xue-lei,et al.Exploring Mechanism of Modified Fuzi Lizhongtang in Intervening Inflammatory Response of Intestinal Mucosa in Rats with Ulcerative Colitis Based on mTOR/p-S6K1[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(13):59-65. DOI： 10.13422/j.cnki.syfjx.20201340.

摘要

目的

探讨加味附子理中汤治疗溃疡性结肠炎（UC）模型大鼠的疗效及相关作用机制。

方法

选用72只雄性SD大鼠，分为正常组，模型组，柳氮磺胺嘧啶组（0.5 g·kg

-1

），加味附子理中汤高、中、低剂量组（23.62，11.81，5.91 g·kg

-1

）。运用2，4，6-三硝基苯磺酸（TNBS）-乙醇复合造模法复制UC大鼠模型，连续灌胃治疗2周，观察各组大鼠一般情况，大鼠麻醉后腹主动脉采血，取结肠组织。运用结肠黏膜损伤指数（CMDI）半定量评分，苏木素-伊红（HE）染色观察大鼠结肠组织病理学改变，酶联免疫吸附测定（ELISA）检测大鼠血清白细胞介素（IL）-4，IL-6，IL-10，肿瘤坏死因子-

（TNF-

）含量；免疫组化和蛋白免疫印迹法（Western blot）分别检测结肠黏膜组织哺乳动物雷帕霉素靶蛋白（mTOR）及磷酸化核糖体蛋白S6激酶1（p-S6K1）蛋白表达。

结果

与正常组比较，模型组大鼠CMDI评分显著升高（

0.01），血清IL-4，IL-10含量显著下降，IL-6，TNF-

含量显著上升（

0.01），结肠黏膜组织mTOR，p-S6K1蛋白表达水平显著上调（

0.01）；与模型组比较，加味附子理中汤高剂量组大鼠CMDI评分明显下降（

0.05），高、中剂量组大鼠血清促炎因子IL-6，TNF-

显著降低（

0.01），抗炎因子IL-4，IL-10明显升高（

0.05，

0.01）；加味附子理中汤高剂量大鼠mTOR，p-S6K1的蛋白表达水平明显下调（

0.05，

0.01）。

结论

加味附子理中汤高剂量组可显著减轻UC结肠黏膜充血水肿、炎性细胞浸润、腺体扭曲、排列紊乱等病理表现，其机制可能与其下调mTOR/p-S6K1信号、调控炎症因子的分泌有关。

Abstract

Objectives

To investigate the therapeutic effect and mechanism of modified Fuzi Lizhongtang on ulcerative colitis （UC） model rats.

Method

The 72 male SD rats were randomly divided into normal group，model group，sulfasalazine group（0.5 g·kg

-1

），modified Fuzi Lizhongtang high，medium and low-dose group （23.62，11.81，5.91 g·kg

-1

）. These rats were used to replicate the UC rat model by 2，4，6-trinitrobenzene sulfonic acid （TNBS）-ethanol composite modeling and treated by gavage for 2 weeks. The general condition of rats in each group was observed. After anesthesia，blood was collected from abdominal aorta and colonic tissue was taken. Semi quantitative evaluation by the colon mucosa damage index （CMDI），the pathological changes of colonic tissue were observed by the hematoxylin and eosin （HE） staining. The contents of serum interleukin-4 （IL-4），IL-6，IL-10 and tumor necrosis factor-

（TNF-

） were detected by enzyme-linked immunosorbent assay （ELISA）. The expressions of mammalian target of rapamycin（mTOR） and phosphorylated ribosomal protein S6 kinase 1 （p-S6K1） in colonic mucosa were detected by immunohistochemistry （IHC） and Western blot.

Result

Compared with normal group，the CMDI score of the model group rats was significantly increased （

0.01）. The contents of IL-4 and IL-10 in serum were significantly decreased，the contents of IL-6 and TNF-

were significantly increased （

0.01）. The expression levels of mTOR and p-S6K1 in colonic mucosa were up-regulated （

0.01）. Compared with model group，the CMDI score of the modified Fuzi Lizhongtang high dose group was significantly decreased （

0.05）. In modified Fuzi Lizhongtang high and medium dose group，the contents of IL-6 and TNF-

were significantly decreased （

0.01） and the contents of IL-4 and IL-10 in serum were significantly increased （

0.05，

0.01）. In the modified Fuzi Lizhongtang high dose group，the expression level of mTOR and p-S6K1 protein was down-regulated significantly （

0.05，

0.01）.

Conclusion

Modified Fuzi Lizhongtang high dose group can significantly reduce the congestion and edema，inflammatory cell infiltration，gland distortion，disorder of arrangement and other pathological manifestations of UC colon mucosa，and its mechanism may be related to its down-regulation of mTOR/p-S6K1 signal and the regulation of inflammatory factors secretion.

关键词

Keywords

references

ZENG Z ， ZHU Z ， CHEN M ， et al . Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong province，China: a prospective population-based study [J]. J Gastroenterol Hepatol ， 2013 ， 28 （ 7 ）: 1148 - 1153 .

YANG H ， LI Y ， WU W ， et al . The incidence of inflammatory bowel disease in Northern China: a prospective population-based study [J]. PLoS One ， 2014 ， 9 （ 7 ）: e101296 .

STEINHART A H ， FERNANDES A . Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis:the patient perspective [J]. Can J Gastroenterol Hepatol ， 2015 ， 29 （ 6 ）: 294 - 296 .

BRESSLER B ， MARSHALL J K ， BERNSTEIN C N ， et al . Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis:the Toronto consensus [J]. Gastroenterol ， 2015 ， 148 （ 5 ）: 1035 - 1058 .

张声生，赵鲁卿 . 溃疡性结肠炎的中医治疗策略和思考 [J]. 中国中西医结合消化杂志， 2016 ， 24 （ 6 ）: 411 - 413 .

LYONS J ， GHAZI P C ， STARCHENKO A ， et al . The colonic epithelium plays an active role in promoting colitis by shaping the tissue cytokine profile [J]. PLoS Biol ， 2018 ， 16 （ 3 ）: e2002417 .

JOHNSON S C ， RABINOVITCH P S . mTOR is a key modulator of ageing and age-related disease [J]. Nature ， 2013 ， 493 （ 7432 ）: 338 - 345 .

LAPLANTE M ， SABATINI D M . MTOR signaling in growth control and disease [J]. Cell ， 2012 ， 149 （ 2 ）: 274 - 293 .

JIANG Z ， CHEN Z ， CHEN Y ， et al . Involvement of pro-inflammatory cytokines in diabetic neuropathic pain via central PI3K/Akt/mTOR signal pathway [J]. Arch Physiol Biochem ， 2019 ， doi： 10.1080/13813455.2019.1651869 http://dx.doi.org/10.1080/13813455.2019.1651869 .

JIANG W ， HAN Y P ， HU M ， et al . A study on regulatory mechanism of miR-223 in ulcerative colitis through PI3K/Akt-mTOR signaling pathway [J]. Eur Rev Med Pharmacol Sci ， 2019 ， 23 （ 11 ）: 4865 - 4872 .

张少华，毕经旺 . 结直肠癌组织中S6K1及4EBP1蛋白的表达及其与临床病理特征的关系 [J]. 中国肿瘤生物治疗杂志， 2015 ， 22 （ 6 ）: 747 - 753 .

姬培震，张怡，李雪萍，等 . 附子理中汤灌肠对脾肾阳虚型溃疡性结肠炎大鼠NF- κ B，TNF- α ，IL-1 β 表达的影响 [J]. 中国实验方剂学杂志， 2015 ， 21 （ 14 ）： 124 - 128 .

张艳晓，方锐洁，白少玉，等 . 附子理中汤灌肠调控溃疡性结肠炎大鼠IL-6、IL-8及ICAM-1的实验研究 [J]. 中国中医基础医学杂志， 2016 ， 22 （ 3 ）: 351 - 354 .

王燚霈，朱莹，王璇 . 溃疡性结肠炎（脾肾阳虚模证）大鼠模型的实验研究 [J]. 中国中医急症， 2015 ， 24 （ 8 ）： 1332 - 1334，1391 .

陈奇 . 中药药理研究方法学 [M]. 北京 : 人民卫生出版社， 2006 : 18 .

CROMER W E ， GANTA C V ， PATEL M ， et al . VEGF-A isoform modulation in an preclinical TNBS model of ulcerative colitis: protective effects of a VEGF164b therapy [J]. J Transl Med ， 2013 ， 11 （ 1 ）： 207 .

赵广刚 . 附子理中汤治疗溃疡性结肠炎的临床疗效及其安全性 [J]. 临床合理用药杂志， 2019 ， 12 （ 24 ）: 28 - 29 .

崔晓娟，奉建芳，陈颖，等 . 基于网络药理学分析龙血竭缓解实验性溃疡性结肠炎小鼠结肠黏膜损伤的作用机制 [J]. 中草药， 2019 ， 50 （ 16 ）: 3872 - 3879 .

GYORGYI M ， BÉLA M ， ZSOLT T ， et al . Changes of the cytokine profile in inflammatory bowel diseases [J]. World J Gastroenterol ， 2012 ， 18 （ 41 ）: 5848 - 5861 .

王彤，王骁，范焕芳，等 . 白头翁汤对溃疡性结肠炎模型小鼠结肠黏膜及血清 TNF- α ，IL-6影响 [J]. 辽宁中医药大学学报， 2017 ， 19 （ 2 ）: 32 - 35 .

李婷，朱向东，杨意，等 . 痛泻要方对溃疡性结肠炎大鼠下丘脑中IL-6，IL-6R表达的影响 [J]. 中国实验方剂学杂志， 2017 ， 23 （ 11 ）: 103 - 108 .

LI Y ， DE HAAR C ， CHEN M ， et al . Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis [J]. Gut ， 2010 ， 59 （ 2 ）: 227 - 235 .

NIELSEN O H ， KØPPEN T ， RÜDIGER N ， et al . Involvement of interleukin-4 and -10 in inflammatory bowel disease [J]. Dig Dis Sci ， 1996 ， 41 （ 9 ）: 1786 - 1793 .

HU S ， CHEN M ， WANG Y ， et al . MTOR inhibition attenuates dextran sulfate sodium-induced colitis by suppressing T cell proliferation and balancing TH1/TH17/Treg profile [J]. PLoS One ， 2016 ， 11 （ 4 ）: e0154564 .

BHONDE M R ， GUPTE R D ， DADARKAR S D ， et al . A novel mTOR inhibitor is efficacious in a murine model of colitis [J]. Am J Physiol Gastrointest Liver Physiol ， 2008 ， 295 （ 6 ）: 1237 - 1245 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring Mechanism of Different Processed Products of Baiyaojian and Its Formula in Treating Ulcerative Colitis Based on Serum Metabolomics and Flow Cytometry

Effect of Mankuining Formula on NLRP3/Caspase-1/GSDMD Pyroptosis Pathway and Gut Microbiota in DSS-induced Ulcerative Colitis Mice

Effect of Mankuining Decoction on Expression of Inflammatory Factors and Intestinal Flora in Mice with Ulcerative Colitis

Clinical Observation on Jiechang Qingre Pills Combined with Conventional Western Medicine Therapy in Improving Dampness-heat Syndrome of Large Intestine at Active Stage of Ulcerative Colitis

Regulatory Effect of Huaihuasan Combined with Taohuatang on Immune Inflammation During Active Period of Ulcerative Colitis with Cold-heat Syndrome

Related Author

WANG Ruisheng

HOU Yafang

CAO Wenwen

ZHAO Yahong

ZHANG Zhenling

JI Yongkuan

NI Ruifan

LIANG Yanlin

Related Institution

Henan Collaborative Innovation Center for Research and Development on the Whole Industry Chain of Yu-yao，Henan Engineering Research Center of Chinese Traditional Medicine Special Processing Technology， Henan Engineering Technology Research Center for Integrated Production of Chinese Medicine， Henan Provincial Key Laboratory of Traditional Chinese Medicine for Decoction Pieces Processing， Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province & Ministry of Education，Henan University of Chinese Medicine

School of Traditional Chinese Medicine， Beijing University of Chinese Medicine

Second Clinical Medical College， Henan University of Chinese Medicine

Henan Province Hospital of TCM The Second Affiliated Hospital of Henan University of Chinese Medicine

Anorectal of Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰